Certificate under Regulation 74(5) of SEBI (DP) Regulation 2015 for Q ended 31.12.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sandu Pharmaceuticals has submitted a routine quarterly compliance certificate under SEBI Regulation 74(5) for the quarter ended 31 December 2025. The certificate was issued by the company's Registrar and Share Transfer Agent, MUFG Intime India Pvt. Ltd. (formerly Link Intime). It confirms that all share dematerialisation requests received during the quarter were processed, confirmed or rejected to the depositories (NSDL and CDSL), and that physical share certificates received were mutilated and cancelled with the depository names updated in the register of members within the prescribed timelines. The filing was made to BSE, CDSL, and NSDL on 7 January 2026. This is a standard procedural submission that every listed company must file each quarter.
This is a routine regulatory compliance filing with no impact on business operations, financials, or share price. It simply confirms that share dematerialisation activities during the October–December 2025 quarter were handled properly by the RTA.